Document is current

Any future updates will be listed below

Correction to: Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS study

Crossref DOI link: https://doi.org/10.1007/s00277-024-06020-3

Published Online: 2024-09-23

Published Print: 2024-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark